Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
The authors of the study concluded that the GLP-1 receptor agonist lixisenatide had a three-point beneficial effect, when compared with placebo, in the change over a 12-month period from a baseline value of approximately 15 points on a 132-point scale measuring motor disability. The active arm improved 0.04 points in the lixisenatide group and worsened 3.04 points in the placebo group
References NIH: GLP-1 Receptor Agonists Cleveland Clinic: GLP-1 Agonists AJMC: Top GLP-1 Agonists GoodRx: GLP-1 Drugs Comparison Mayo Clinic: Byetta FAQ
Sherer, Y
Competing interests: All authors have read and approved of the contents of the manuscript and none of the authors have competing financial interests
WADA tried a new definition of doping
US$ 27.08
US$ 25.82
US$ 20.17
US$ 23.79
US$ 20.55
US$ 24.22
US$ 26.80
US$ 25.90
